

HepaRG cells as human relevant in vitro model to study the effects of inflammatory stimuli on Cytochrome P450 isoenzymes

Katarina Rubin, Annika Janefeldt, Linda Andersson, Zsofia Berke, Ken Grime and Tommy B Andersson.

Respiratory, Inflammation & Autoimmunity Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, Sweden (KR, KG)

Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, Sweden (AJ)

In Vitro In Silico DMPK AstraZeneca R&D, Mölndal Sweden (LA)

Personalized Healthcare and Biomarkers, AstraZeneca R&D, Mölndal Sweden (ZB)

Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal, Sweden and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (TBA)

HepaRG cells and effects of IL-6, IL-18 and LPS on P450

Corresponding author: Katarina Rubin

Department of DMPK, Respiratory, Inflammation and Autoimmune Disease, AstraZeneca R&D, Mölndal, SE 43183 Mölndal, Sweden. Tel: +46 31 7762762, FAX: +46 (0)317762800
katarina.rubin@astrazeneca.com

Number of text pages: 35

Number of tables: 3

Number of figures: 3

Number of references: 40

Number of words in abstract: 250

Number of words in introduction: 681

Number of words in discussion: 1499

Abbreviations:

BM, Basal medium; C/EBP β , CCAAT enhancer binding protein β ; CAR, Constitutive Androstane Receptor; C/EBP β -LIP, liver-enriched transcriptional inhibitory protein; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FXR, Farnesoid X receptor; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; HepaRG, Human hepatoma cell line; HNF, Hepatic nuclear factor; huPO, Human acidic ribosomal phosphoprotein; IFN γ , interferon- γ ; IL, interleukin; LPS, Lipopolysaccharide; LXR, Liver X receptor; MAS,

macrophage activation syndrome; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; PPARa, Peroxisome proliferator activated receptor; PXR, Pregnane X Receptor; RA, Rheumatoid Arthritis; RXRa, retinoid X receptor; IL-6r, IL-6 receptor; IL-18r, IL-18 receptor.

Abstract

The suppression of hepatic Cytochrome P450 (P450) expression during inflammatory and infectious diseases and the relief of this suppression by successful disease treatment have been previously demonstrated to impact drug disposition. To address this clinically relevant phenomenon preclinically, the effect of pro-inflammatory cytokines on P450 isoenzymes in human hepatocytes has been examined by several researchers. In the present study we used the human hepatoma cell line HepaRG and cryopreserved primary human hepatocytes to investigate the effects of various inflammatory stimuli on P450 levels with the aim of further characterizing HepaRG cells as a useful surrogate for primary hepatocytes. In this study, HepaRG cells were exposed to bacterial lipopolysaccharide (LPS), interleukin-6 (IL-6) and interleukin-18 (IL-18) for 48 or 72 hours. The effects on CYP1A2, CYP2B6 and CYP3A4 mRNA and catalytic activity (phenacetin-O-deethylase, bupropion-hydroxylase and midazolam-1'-hydroxylase) were measured. Cryopreserved pooled plateable hepatocytes were also exposed to IL-6 or IL-18 for 48 hours and the effects on CYP1A2, CYP2B6 and CYP3A4 mRNA levels were measured. The exposure of HepaRG cells to IL-6 and LPS resulted in suppression of and CYP1A2, CYP2B6 and CYP3A4 mRNA levels as well catalytic activities. However, no suppression of P450 activities or mRNA levels was observed after exposure to IL-18. Similar results on CYP1A2, CYP2B6 and CYP3A4 mRNA levels were observed with primary hepatocytes. The present study indicates that different pro-inflammatory mediators influence the expression of P450 differentially and that HepaRG cells may be used as an alternative to human hepatocytes for studies on cytokine-mediated suppression of drug-metabolizing enzymes.

Introduction

Pro-inflammatory cytokines can impact the transcriptional regulation of P450 enzymes. Thus, due to elevated levels of some circulating cytokines in chronic inflammatory disease conditions, expression levels and activity of these drug metabolizing enzymes can be affected (Shedlofsky et al., 1994; Morgan et al., 2001; Kulmatycki and Jamali 2005). This phenomenon is of importance when taking account of pharmacokinetic differences between healthy and diseased subjects, as well as when considering the introduction of novel anti-inflammatory therapies. Depending on the type of therapy, there may be a decrease in circulatory pro-inflammatory cytokine levels and associated increases in expression and activity of certain P450s. This may have a direct effect on the metabolism of other administered drugs, potentially decreasing their exposure and efficacy (Huang et al., 2010). In vitro studies using human hepatocytes can facilitate the understanding as to the relevance of such events and help in making predictions of clinical outcomes.

Cytokine mediated P450 regulation has been studied previously in primary human hepatocytes in vitro, with different cytokines demonstrating clear effects measured both at the transcriptional and functional activity level (Sunman et al., 2004; Aitken et al., 2006; Christensen, 2012). The mechanisms behind this P450 regulation have been investigated and the NF κ B dependent inflammatory response and associated re-localization and dimerization of nuclear receptors such as RXRa, LXR, FXR, CAR, PXR and PPARa has been implicated (Jover et al., 2002, Yang et al., 2010; Ghose et al., 2011). However, P450 specific transcriptional regulation has not fully been characterized, and the question of common pathways versus specific receptor dependent intracellular signaling pathways is still to be elucidated.

IL-6 is a primary mediator of the acute phase response and is a central inflammatory mediator in several chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis and

atherosclerosis (Arican et al., 2005; Rose-John et al., 2007; Barnes et al., 2011). The effect of IL-6 on primary human hepatocytes has been documented with the expression of several P450s down regulated (Jover et al., 2002; Aitken and Morgan, 2007, Vee et al., 2009; Dickmann et al., 2011). In HepaRG cells, IL-6 and lipopolysaccharide (LPS), were previously shown to up regulate C-reactive protein (CRP) and down regulate CYP3A4 mRNA (Aninant et al., 2008). Moreover, drug clearance in cancer patients has been shown to inversely correlate with circulating IL-6 levels (Rivory et al., 2002), whilst treatment of rheumatoid arthritis patients with the anti IL-6 antibody drug Tocilizumab has been shown to directly affect CYP3A4 activity (Schmitt et al, 2011). Such clinical observations have been further strengthened by preclinical studies, assessing the mechanism of IL-6 and IL-6 antagonizing antibody dependent P450 regulation in primary human hepatocytes (Dickmann et al., 2011).

IL-18 is also a potent inflammatory mediator, belonging to a different family of cytokines, the IL-1 family and playing a role in chronic inflammatory conditions and autoimmune diseases (Okamura et al., 1995; Smith, 2011). Accordingly, plasma levels of IL-18 are elevated in patients suffering from chronic obstructive pulmonary disease (COPD), macrophage activation syndrome (MAS) and atherosclerosis and may be used as a potential independent disease risk factor indicator (Gracie et al, 2003; Dinarello, 2007). The specific effect of IL-18 on hepatocytes or regulation of P450 enzymes has not been described previously.

In the present study we investigated the effects of IL-6, IL-18 and the bacterial endotoxin lipopolysaccharide (LPS) on mRNA levels and phenacetin-O-deethylase, bupropion-hydroxylase and midazolam-1'-hydroxylase activities reflecting CYP1A2, CYP2B6 and CYP3A4 function in the human hepatoma cell line, HepaRG. We also investigated these effects of IL-6 and IL-18 on mRNA levels in cryopreserved pooled primary human

hepatocytes. Since up-regulation of acute-phase proteins also forms part of the coordinated pro-inflammatory response mediated through cytokine/cytokine receptor interaction, we investigated the impact of IL-6, IL-18 and LPS treatment on C-reactive protein (CRP) and determined the levels of IL-6 and IL-18 receptors in both the primary and HepaRG hepatocytes. The aim of this study was to characterize the effects of IL-18 and to compare these with the well documented case of IL-6. In doing this we investigated whether cryopreserved HepaRG cells could be an alternative to human hepatocytes for studies of P450 regulation by inflammatory stimuli.

Materials and Methods

Reagents and Chemicals. Cryopreserved differentiated HepaRG[®] cells (batch HPR116062 at passage 16), type I collagen coated 96-well multi well plate, cell culture media (basal hepatic cell medium, additives for Thaw, Seed and General Purpose HepaRG medium, additives for Serum-free induction HepaRG medium), were purchased from Biopredic International (Rennes, France). Single freeze pooled plateable human hepatocytes Cryotax[™], (pool of five individuals, 2 males and 3 females), Hepatocyte Isolation Kit containing Percoll solution and Supplemented Media for isolation and Trypan blue to obtain accurate cell yield and viability (K2000), Resuspension Media, for seeding (K2200) and Hepatocyte Culture Media for dosing cultured hepatocytes (K2300) were purchased from Tebu-bio, (Le Perray-en-Yvelines, Cedex). Type I coated 24-well multi well plate was purchased from Becton Dickinson, (Two Oak Park, Bedford, MA). William's medium E (with NaHCO₃, without L-glutamine and phenol red) was purchased from Sigma-Aldrich (St Louis MO, USA). L-glutamine and HEPES, were purchased from Gibco Invitrogen (Paisley, UK). Acetonitrile, methanol and isopropyl alcohol were purchased from Rathburn Chemicals Ltd (Walkerburn, Scotland), formic acid from Sigma Aldrich (St Louis, MO, USA), sodium hydroxide from Akzo Nobel (Bohus, Sweden) and ethanol from Kemetyl (Haninge, Sweden). Chloroform was purchased from Scharlau Chemie S.A (Barcelona, Spain). Recombinant human IL-6 and IL-18 were purchased from R&D (Abingdon, UK), LPS from E.coli was purchased from Sigma Aldrich (St Louis, MO, USA).

Trizol[®] Reagent for isolation of RNA, TaqMan[®] Gene Expression Assays, TaqMan[®] Universal Master Mix, SuperScript III First-Strand Synthesis System for RT-PCR, 20xTe buffer (Tris HCL+EDTA) were purchased from Applied Biosystems, Invitrogen (Eugene Oregon, USA). The primers and probes were purchased from Applied Biosystems (Cheshire, UK). Phenacetin was purchased from Sigma-Aldrich (St Louis, MO, USA). Bupropion was

purchased from Kemprotec Ltd (Middlesbrough, UK), midazolam from Lipomed (Switzerland), paracetamol from Sigma-Aldrich (St Louis, MO, USA), hydroxybupropion from Toronto Research Chemicals (North York, Canada) and 1'-hydroxymidazolam from Ultrafine UFC Limited (Manchester, UK).

The internal standards, paracetamol-d₄ and 1'-hydroxymidazolam-¹³C₃ were purchased from Toronto Research Chemicals (North York, Canada) and hydroxybupropion-d₆ from Becton Dickinson, (Two Oak Park, Bedford, MA).

HepaRG Cell culturing, LPS and Interleukin exposure. The cryopreserved HepaRG cells were thawed and washed as follows:

The tubes were wiped with 70% ethanol and the cap was briefly twisted and immediately closed under the laminar flow hood, to release the internal pressure. The vials were quickly transferred to a 37°C water bath and gently agitated for 1-2 minutes. When only small ice crystals were remaining in the vials, they were removed from the water bath. The thawed HepaRG cell suspension was transferred into an aseptic 50 mL Falcon tube containing 9 mL/cryo vial of pre-warmed (37°C) HepaRG Thaw, Seed and General Purpose Medium (MIL670). The cryo vials were rinsed once with approximately 1 mL of the MIL670 and the suspension was returned in to the Falcon tube. The HepaRG cells were centrifuged at 357g for 2 minutes at room temperature. The supernatant was removed and the pellet was re-suspended in 5 mL of MIL670 and amount of cells and viability were determined by Trypan Blue cell count analysis. The cell suspension was seeded into flat-bottom multi-well plates, (100 µL/well, 0.72x10⁶ cells/mL) coated with rat tail type I collagen. The cells were maintained at 37°C in an atmosphere of 95% air and 5% CO₂. After 6 hours, the cell morphology was checked and the medium was renewed with pre-warmed Thaw, Seed and General Purpose Medium (MIL670). After 72 hours the HepaRG Thaw, Seed, and General

Purpose Medium 670 was removed and replaced with the HepaRG Serum-free Induction Medium 650 including LPS (1.37-333 ng/mL), IL-6 (0.123-30 ng/mL) or IL-18 (2.06-500 ng/mL). Negative controls, exposed to Serum-free Induction Medium 650 (basal medium, BM) were run in parallel. The HepaRG cells were exposed for 48 hours (mRNA) or 72 hours (enzyme activity) and the medium was renewed every 24 hours. The medium was always pre-warmed to room temperature before addition to the cells (100 μ L/well). Activity and mRNA incubations were performed in three plates respectively, where two or three wells per plate were exposed to LPS, IL-6, or IL-18. For negative control (BM) incubates, six wells per plate were used.

Primary Human Hepatocyte Cell culturing and Interleukin exposure. The cryopreserved pooled human hepatocytes were thawed and washed as follows:

The tubes were wiped with 70% ethanol under the laminar flow hood. The content of the vials were immediately dispensed into a 50 mL tube containing prewarmed Supplemented Media, with Penicillin (50 U/mL), Streptomycin (50 μ g/mL) and isotonic PercollTM (K2000). The tube was gently inverted until all ice was melted and centrifuged at 100 g for 5 minutes at room temperature. The supernatant was discarded and the cell pellet was re-suspended in nutrient rich Hepatocyte Re-Suspension media (K2200). Amount of cells and viability were determined by Trypan Blue cell count analysis. The cell suspension was seeded into flat-bottom multi-well plates, (300 μ L/well, 1.3×10^6 cells /mL) coated with rat tail type I collagen. The cells were allowed to attach for 6 hours in a 37°C humidified static incubator with an atmosphere of 95% air and 5% CO₂. After 6 hours, cell morphology was checked and the cells were washed and replaced with pre-warmed Hepatocyte Culture Media (2300). After 24 hours the media was replaced with fresh Hepatocyte Culture media including IL-6 (0.006-50 ng/mL) or IL-18 (1.95-500 ng/mL). The medium was always pre-warmed to 37°C before addition to the cells (350 μ L/well) and was renewed every 24 hours. Single (IL-18) or

duplicate (IL-6 and negative control) incubations were performed during 48 hours and negative controls were exposed to Hepatocyte Culture Media.

RNA extraction. Total RNA from HepaRG cells and the primary hepatocytes was prepared after 48 hours exposure to LPS, IL-6, or IL-18 by using TRIzol[®] reagent according to the manufacturer's protocol. For HepaRG, samples of each concentration of the compounds were pooled giving a final volume of 200 μ L (negative control) and 200 μ L or 300 μ L (LPS and IL- exposed cells) for mRNA extraction. The final volume for the human hepatocytes was 300 μ L. Quantity and purity of the RNA were determined spectrophotometrically using a NanoDrop (Saveen Werner AB, Limhamn, Sweden). Based on optimization of linearity the cDNA was prepared from 800 ng (HepaRG) and 600 ng (hepatocytes) of total RNA using the SuperScript[™] III First-Strand Synthesis System for reverse transcription-PCR with random hexamer primers according to the manufacturer's protocol.

Real-time RT-PCR. Real-time PCR for human P450 mRNA levels was performed using quantitative real-time PCR employing TaqMan[®] Gene Expression Assay with specific primers and probes for CYP1A2, CYP2B6, CYP3A4, CRP, IL-6, IL-18 and the receptor for IL-6 and IL-18. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and human acidic ribosomal phosphoprotein (huPO) were used as endogenous gene expression control. For human acidic ribosomal phosphoprotein (huPO), gene-specific double fluorescent labeled probes were used as reported previously (Persson et al., 2006). The reaction mixture (25 μ L/well) contained 46 ng (HepaRG) or 34 ng (Hepatocytes) of cDNA, 2xTaqman Universal Master Mix, 1.25 μ L Gene Expression Assay Mix as well as RNase free water. The thermal cycle conditions were identical for all the genes analyzed and had initial steps of 50°C for 2 min and a 10 minutes step at 95°C, followed by 40 PCR cycles of 95°C for 15 seconds and 60°C for 1 minute. Each sample was run in duplicate and data were analyzed using the 7500

Sequence detector software version 1.3.1 (Applied Biosystems, Foster City, CA). The amount of mRNA was determined relative to that from control samples.

Activity measurement in HepaRG cells. For cells used for activity measurements, induction medium was renewed every 24 hours and after 72 hours the medium was removed. The cells were washed twice with 100 μ L pre-warmed (37°C) William's medium E, supplemented with 2 mM L-glutamine and 25 mM HEPES (pH 7.4). A cocktail of phenacetin (26 μ M), bupropion (100 μ M) and midazolam (3 μ M) (final concentrations) was prepared by dissolving the compounds in methanol. The methanol was taken to dryness under nitrogen gas, so that the activity medium did not include any organic solvent and the compounds were re-dissolved in William's medium E with supplements to reach the intended concentration in the activity assay. The cocktail was pre-warmed and added to the wells (50 μ L/well). After 60 minutes of incubation, the medium (50 μ L) was removed and transferred to a new plate, which was covered with a lid and stored at 4°C. The cells were lysed by adding ice-cold acetonitrile containing 0.8% formic acid (50 μ L/well). To completely lyse the cells, the plates were subjected to three freezing-thawing cycles (3 x (20 min freezing and 10 min thawing)). The resulting cell lysate was transferred and mixed with the corresponding well containing the supernatant incubation medium. The plates were centrifuged at 3220 g for 20 minutes at 4°C. An aliquot (52 μ L) of each sample was transferred to a new plate and diluted with 148 μ L water supplemented with 25 μ L isotope labeled internal standards (IS) (paracetamol d₄, hydroxybupropion-d₆ or 1'-hydroxymidazolam-¹³C₃). The samples were analyzed immediately after preparation.

The samples were analyzed by LC/MS for the metabolites of the marker substrates paracetamol (CYP1A), hydroxybupropion (CYP2B6) and 1'-hydroxymidazolam (CYP3A) and for the internal standards. HPLC separation was achieved using a 10 μ L injection volume on to a reversed-phase Halo C18 column (3.0x50 mm, 2.7 μ m), Advanced Materials

Technology, DE, USA) with a flow rate of 750 $\mu\text{L}/\text{min}$. The mobile phase consisted of (A) 50 mL acetonitrile, 1.0 mL formic acid and 950 mL water and (B) 950 mL acetonitrile, 1.0 mL formic acid and 50 mL water and was run for 3.10 minutes (5% B to 95% B over 2.3 minutes; 0.2 minutes at 95% B; 95% B to 5% B over 0.2 minutes and 0.4 minutes equilibration at 5% B before the next injection). Detection was performed with a triple quadrupole mass spectrometer, API4000, equipped with electrospray interface (Applied Biosystems/MDS Sciex, Concord, Canada). The MS parameters were optimized using each analyte. Instrument control, data acquisition and data evaluation were performed using Applied Biosystems/MDS Sciex Analyst 1.4 software.

Data evaluation of activity results. Fold reduction was calculated for IL-6, IL-18 and LPS treated cells using basal medium (BM) treated cells as a control. Mean values from treated cells were used for calculation. Mean values were calculated from three different plates and three replicates per plate.

Data evaluation of gene expression results. Quantification of relative gene expression and fold induction was performed using the ΔC_T and the $\Delta\Delta C_T$ method respectively:

The expression in each sample was normalised by subtracting the endogenous control Ct values (GAPDH and huPO) from the target Ct value (CYP, IL, CRP) (Equation 1).

$$\Delta C_t = C_{t_{\text{CYP, IL, CRP}}} - C_{t_{\text{GAPDH, huPO}}} \quad (1)$$

$$\text{Relative gene expression level was calculated as } 2^{-\Delta C_t} \quad (2)$$

Fold changed was calculated for IL-6, IL-18 and LPS treated cells using basal medium treated cells as a calibrator (Equation 3 and 4).

$$\Delta\Delta C_T = \Delta C_{t_{\text{compound treated}}} - \Delta C_{t_{\text{basal medium treated}}} \quad (3)$$

$$\text{Fold changed} = 2^{-\Delta\Delta Ct} \quad (4)$$

Mean values from treated cells involving three different plates, with two or three pooled replicates per plate, were used in the calculations for HepaRG. Individual and mean results were used for the cryopreserved primary human hepatocytes, with mRNA levels measured from one plate with single (IL-18) or duplicate (IL-6) incubations.

The response relationship between mRNA or CYP activity and IL-6 and LPS concentration was determined using a four-parameter logistic non-linear regression analysis in Xlfit:

$$v = A + \frac{B - A}{1 + ([I] / IC_{50})^D}$$

where v is the fold change to control in activity or mRNA, [I] is the log of IL-6 or LPS concentration, A and B are the lowest and highest activity or mRNA response (% of control) and D is the Hill slope of the curve.

Results

The human hepatoma cell line HepaRG was exposed to a range of concentrations of LPS (1.37-333 ng/mL) and the cytokines IL-6 (0.123 ng/mL to 30 ng/mL) and IL-18 (2.06-500 ng/mL) for 48 hours (mRNA analyses) and 72 hours (enzyme activity measurements). The primary hepatocytes were exposed to IL-6 (0.006-50 ng/mL) and IL-18 (1.95-500 ng/mL) for 48 hours prior to mRNA analysis. The results refer to enzyme activity and mRNA levels, relative to the negative control (BM treated cells), at the highest nominal LPS or cytokine concentration tested (E_{\min}) and the concentration of IL-6, IL-18 or LPS required to cause 50% decrease in P450 activity or mRNA (EC_{50}). The levels of IL-6 and IL-18 mRNAs and the expression of their receptors were measured in the negative control samples. The slopes of amplification indicate equal amplification efficiencies and the delta Ct values were thus used to compare the expression levels in the two cell types. These delta Ct values suggest very similar levels of IL-6r mRNA in both cell systems. Whilst the same was true also for IL-18r and IL-6 mRNA, the data suggest a 4 fold higher level of IL-18 mRNA in the hepatocytes as compared with HepaRG cells (Figure 1). The expression of IL-6 was 16- and 7-fold lower than the expression of IL-18 in primary hepatocytes and HepaRG cells respectively, whilst the expression of IL-6r was 13- and 29-fold higher in hepatocytes and HepaRG cells, respectively compared to IL-18r (Figure 1).

The degree of inflammatory response by IL-6 and IL-18 was assessed by measuring the mRNA of C-reactive protein, (CRP). IL-6 caused an increase of CRP mRNA level in HepaRG cells and primary human hepatocytes, but no induction of CRP mRNA could be seen in cells exposed to IL-18 in the two cell systems (Fig.2).

A decrease in mRNA levels, with a clear dose response was observed for all P450s studied within the concentrations tested of IL-6 in HepaRG treated cells and primary cells (Fig. 3). The EC_{50} and the E_{\min} estimates showed that the potency and the extent of activity and gene

suppression varied among the P450 isoforms for both HepaRG and primary cells treated with LPS and IL-6 (Table 1, Table 2 and Table 3). IL-6 caused the greatest effect on both activity in the HepaRG cells and mRNA levels in the two cell systems with an EC_{50} below 10 ng/mL for all P450 isoforms (Table 1, Table 2 and Table 3). Similar potency was noted for LPS treated HepaRG cells on CYP3A4, with an EC_{50} below 10 ng/mL. CYP1A2 and CYP2B6 were less sensitive to suppression by LPS and no significant decrease in enzyme activity or gene expression was seen for IL-18 treated cells at the concentrations tested in HepaRG cells or in the cryopreserved human hepatocytes.

Discussion

For the *in vitro* study of the impact of test compounds or external stimuli such as pro-inflammatory mediators on CYP gene regulation and transcription, primary human hepatocytes are regarded as the system of choice, especially when supporting the clinical development of therapeutic agents. Cell lines such as HepaRG are considered as useful for providing supportive data (<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf>; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf). However, limited availability of high-quality, plateable human hepatocytes coupled with the inter-individual variability in P450 levels and response has encouraged the investigation of hepatic cell line utility. Although recent progress in the availability of large batches of pre-characterized inducible cryopreserved primary human hepatocytes has somewhat mitigated the issues, cost is a serious consideration, at least in a Drug Discovery setting. Thus the pursuit of close surrogates to primary cells that can mimic relevant cellular responses, drug metabolizing capacity and regulation of the enzymes involved, continues to be important.

Basal expression of hepatic P450 isoenzymes and response to P450 gene regulators is complex and involves many ligand activated transcription factors such as PXR as well as direct binding transcription factors (Schrem et al. 2002; Schrem et al. 2004). A separate level of control lies in chromatin conformation which dictates transcription factor binding (Phillips et al., 2005). Both processes play key roles in regulating P450 expression and alterations in both are important in understanding not only the decline in P450 expression after isolation of hepatocytes from the intact liver, but also the disparity in P450 expression between isolated primary hepatocytes and some hepatic cell lines (Phillips et al., 2005; Castell et al., 2006). An important factor in the down-regulation of CYP3A4 by IL-6 is the translational induction of a truncated form of CCAAT enhancer binding protein β (C/EBP β), the 20kDa liver-enriched

transcriptional inhibitory protein (C/EBP β -LIP). C/EBP β -LIP hetero-dimerises with the full length C/EBP β to form a dominant negative regulator of P450, since it contains a DNA-binding domain but not a trans-activation domain (Jover et al., 2002; Castell et al., 2006). LPS reduces the DNA binding activities of several Hepatic Nuclear Factors (HNF) and represses CAR, PXR and RXR through activation of the NF κ B pathway (Martinez-Jimenez et al., 2007).

The utility of some hepatic cell lines in the study of drug metabolizing enzymes and hepatic function has been shown to be limited by the deficit in one or more of the extremely complex pathways that make up the fully functioning primary hepatic parenchymal cells (Philips et al, 2005; Castell et al., 2006; Hariparsad et al., 2008; Martin et al., 2008). On the other hand, HepaRG cells are emerging as having wide ranging utility with expression of some, but not all, drug metabolizing enzymes and transporters at levels comparable to primary cells (Kanebratt and Andersson 2008) and CYP inducer response closely mimicking primary cells (McGinnity et al., 2009).

Previous reports have described the direct effect of LPS and IL-6 on the expression and activity of P450 in primary human hepatocytes (Dickmann et al., 2011; Aitken and Morgan, 2007). In the present investigation we used HepaRG cells and cryopreserved primary human hepatocytes to investigate the effects of the previously studied inflammatory stimuli in order to further characterize HepaRG cells as a potentially useful surrogate for primary hepatocytes. Additionally we added IL-18 to the list of investigated mediators, since IL-18 is produced by macrophages and other cells of the immune system to elicit pro-inflammatory effects following infection with microbial products such as LPS. After stimulation with IL-18, T-cells release interferon- γ (IFN γ) to amplify the immune response. The same IL-18 preparation was used in all studies. The concentration range used was chosen based on the observed effects of LPS and IL-18 to induce IFN γ production in primary human leukocytes in

vitro (Puren et al, 1998, Berke, unpublished observations). Physiological concentrations of these cytokines measured in plasma can be quite variable, depending on disease status and possibly medication (Arican et al., 2005). Indeed, plasma concentrations of IL-18 range from around 0.1-0.2 ng/mL in healthy controls but up to 1-2 ng/mL in disease state (Blankenberg et al, 2003, Berke, unpublished observations). IL-6 levels in plasma from non-diseased subjects are typically around 5 pg/mL but can be as high as 50-60 pg/mL in Rheumatoid Arthritis (RA patients) (Robak et al, 1998). Thus the concentration range used in previous publications of in vitro models extends beyond the values measured in clinical plasma samples, but it is difficult to correlate such measurements to local concentrations in the liver (both IL-6 and IL-18 are locally produced and can act in the tissue) and there is a clear correlation between the in vitro measured effects of IL-6 on P450 and the observations in tocolizumab treated RA patients (Schmitt et al, 2011).

When comparing our HepaRG IL-6 EC₅₀ values with those previously reported for primary hepatocytes (Dickmann et al., 2011; Aitken and Morgan, 2007) there is a good degree of agreement between the results. For CYP1A2 phenacetin O-deethylation activity, Dickmann and co-workers reported EC₅₀ values ranging from 0.14 to 4 ng/mL whereas the EC₅₀ determined for CYP1A2 mRNA down regulation was 0.3 ng/mL. The values we report here for HepaRG are 9 ng/mL for activity and 0.4 ng/mL for the mRNA analysis. For suppression of CYP2B6 transcription in HepaRG cells, we found IL-6 to be approximately 4 - 10-fold more potent than Aitken and Morgan (0.5 ng/mL EC₅₀ compared to an estimated value of 2 - 5ng/mL). Our primary hepatocyte EC₅₀ indicated a slightly more potent suppression by IL-6, with an EC₅₀ value of 0.18 ng/mL. Dickmann et al determined an IL-6 EC₅₀ value of 3 pg/mL for CYP3A4 mRNA and values of 4 – 176 pg/mL for activity. From our data we are only able to place the EC₅₀ value in the range < 100 pg/mL for HepaRG mRNA and activity. Aitken and Morgan were also unable to report an IL-6 EC₅₀ value in their study, but

observed a very high level of suppression of CYP3A4 mRNA at 10 ng/mL. Whilst we found reasonable agreement in the Emin and EC50 values obtained based on CYP1A2, 2B6 and 3A4 mRNA analysis following HepaRG and primary hepatocyte experiments in our laboratory, the correspondence does not hold so well when comparing our primary hepatocyte CYP1A2 mRNA data to that of Dickmann et al, there being a 70-fold difference in IL-6 EC50 (our value of 5 ng/mL compared to 0.07 ng/mL). Similarly we estimated 0.5 ng/mL to be the EC50 value in our primary hepatocyte CYP3A4 mRNA assay, considerably less potent than the value estimated by Dickmann et al (3 pg/mL). Our primary hepatocyte study was limited in replicates, however, our principal aim was to corroborate our novel findings indicating a lack of effect of IL-18 on P450 expression, which we first determined in HepaRG cells. Taking this into account and the inter-subject variability in response to IL-6 evident in the P450 activity data presented by Dickmann et al, the inter-lab IL-6 potency differences described above cannot undermine the significance of our findings for HepaRG cells as a substitute for primary hepatocytes and indeed the novel finding that IL-18 does not impact on P450 expression.

In addition to down-regulation of drug metabolising enzymes by pro-inflammatory cytokines, acute-phase proteins including CRP are similarly synthesized in response to infection and tissue injury. In arterial smooth muscle cells both IL-6 and LPS have been shown to induce CRP production (Calabró et al., 2003). IL-6 in particular has been shown to be a potent regulator of acute phase protein synthesis in primary hepatocytes (Castell et al. 1988). Here we also demonstrated that primary hepatocytes and HepaRG cells produced increased levels of CRP mRNA after stimulation with LPS and IL-6 stimulation. Interestingly there was no elevation in CRP mRNA in response to IL-18 treatment, further indicating that different pro-inflammatory cytokines exert different effects on hepatocytes. Whilst there is considerable literature assessing plasma CRP and IL-18 levels as independent risk factors in several

chronic inflammatory diseases and CRP has been implicated as a potential cause of increased circulating IL-18 under inflammatory conditions (Yamaoka-Toyo et al., 2003), the direct effect of elevated IL-18 levels on CRP expression has not been studied previously.

The observation that different cytokines may have diverse effects on P450 isoenzyme transcription is in line with previous data by (Aitken and Morgan 2007). Whether this is a consequence of difference intracellular signaling pathways from the different cytokine receptors is still to be investigated. However, it has been demonstrated previously that nuclear receptors implicated in P450 transcriptional modulation are differentially regulated by cytokines, with the down-regulating effects of IL-1 and IL-6 in human hepatocytes dependent on distinct mechanisms (Assenat et al., 2004, Jover et al., 2002, Martinez-Jimenez et al., 2005).

In summary, this work provides further evidence that many of the complex and multi-faceted control mechanisms for maintaining liver-specific function are operational in HepaRG cells and that this hepatic cell line can, in certain circumstances, be used with full confidence as a surrogate system for primary human hepatocytes. Additionally, IL-18 is distinct from pro-inflammatory LPS and IL-6 in not causing down-regulation of CYP1A2, CYP2B6 and CYP3A4.

Authorship Contributions

Participated in research design: TB Andersson, K Rubin, K Grime, Z Berke, and A Janefeldt.

Conducted experiments: K Rubin and A Janefeldt

Contributed new reagents or analytic tools: Z Berke

Performed data analysis: K Rubin, L Andersson

Wrote or contributed to the writing of the manuscript: K Rubin, K Grime, TB Andersson and

Z Berke.

References

Aninat C, Seguin P, Descheemaeker P-N, Morel F, Malledant Y, Guillouso A (2008) Catecholamines induce an inflammatory response in human hepatocytes. *Crit Care Med* **36**, No.3 848-854.

Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. *Annu Rev Pharmacol Toxicol* **46**:123-149.

Aitken AE and Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. *Drug Metab Dispos* **35**:1687-1693.

Arican O, Aral M, Sasmaz S, and Cigragil P (2005) Serum levels of TNF- α , IFN- γ , IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. *Mediators Inflamm* **5**:273-279.

Assenat E, Serbil-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, and Pascussi JM (2004) Interleukin-1 β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. *Hepatology* **40**:951-960.

Barnes T, Anderson ME, and Moots RJ (2011) The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. *Int J Rheumatol* **2011**:721608.

Blankenberg S, Luc G, Ducimetrière P, Arveiler D, Ferrières J, Amouvel P, Evans C, Vambien F, and Tiret L (2003) Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Circulation* **108**:2453-2459.

Castell JV, Jover R, Martínez-Jiménez CP and Gomez-Lechon, MJ (2006) Hepatocyte cell lines: their use, scope and limitations in metabolism studies. *Expert Opinion in Drug Metabolism and Toxicology* **2**: 183-212.

Castell JV, Maria J. Gomez-Lechbn, Martina David, To&o Hirano,Tadamitsu Kishimoto and Peter C. Heinrich (1988). Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. *Federation of European Biochemical Societies Volume 232, number 2*: 347-350

Christensen H, and Hermann M (2012) Immunological response as a source to variability in drug metabolism and transport. *Front Pharmacol* **3**:8-17.

Calabro P, Willerson JT, Yeh ETH (2003) Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. *Circulation* **108**:1930-1932.

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, and Sletter JG (2011) Effects of interleukin-6 (IL-6) and anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. *Drug Metab Dispos* **39**:1415-1422.

Dinareello CA (2007) Interleukin-18 and the pathogenesis of inflammatory disease. *Semin Nephrol* **27**:98-114.

Gracie JA, Robertson SE, and McInnes IB (2003) Interleukin-18. *J Leukoc Biol* **73**:213-224.

Ghose R, Guo T, Vallejo JG, Gandhi A (2011) Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. *Drug Metab Dispos*. **39**:874-881.

Hariparsad N, Carr BA, Evers R and Chu X (2008) Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. *Drug Metab Dispos*. **36**:1046-1055.

Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, and Lesko LJ (2010) Therapeutic protein-drug interactions and implications for drug development. *Clin Pharmacol Therapeutics* **87**:497-503.

Jover R, Bort R, Gómez-lechón MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanisms and transcription factors involved. *FASEB J* **16**:1799-1801.

Kanebratt KP and Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. *Drug Metab Dispos* **36**:137-145.

Kulmatycki KM and Jamali F (2005) Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. *J Pharm Sci* **8**:602-625.

Martin P, Riley R, Back DJ and Owen A (2008) Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. *Br J Pharmacol*. **153**:805-819.

Martínez-Jiménez CP, Gomez-Lechon MJ, Castell JV, and Jover R (2005) Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhance region responsive to CCAAT/enhancer-binding protein beta isoforms. *Mol Pharmacol* **67**:2088-2101.

Martínez-Jiménez CP, Jover R, Donato MT, Castell JV and Gómez-Lechón MJ (2007) Transcriptional regulation and expression of CYP3A4 in hepatocytes. *Curr Drug Metab*. **8**:185-194.

McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM and Riley RJ (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. *Drug Metab Dispos*. **37**:1259-1268.

Morgan ET (2001) Regulation of cytochrome P450 by inflammatory mediators: why and how? *Drug Metab Dispos* **29**:207-212.

Okamura H, Tsutsui H, Komatsu T, Yutsudo K, Hakura A, Takimoto T, Torigoe K, et al. (1995) Cloning of a new cytokine that induces IFN- γ production by T-cells. *Nature* **378**: 88-91.

Persson KP, Ekehed S, Otter C, Lutz ES, McPheat J, Masirembwa CM., and Andersson TB (2006) Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 reduction in humans. *Pharmaceutical Res* **23**: 59-69.

Phillips A, Hood SR, Gibson GG and Plant NJ (2005) Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression. *Drug Metab Dispos.* **33**:233-242.

Puren AJ, Razeghi P, Fantuzzi G, and Dinarello CA (1998) Interleukin-18 enhances Lipopolysaccharide-induced interferon- γ production in human whole blood cultures. *J Infectious Dis* **178**:1830-1834.

Rivory LP, Slaviero KA, and Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute phase response. *Br J Cancer* **87**:277-280.

Robak T, Gladalska A, Stepień H, and Robak E (1998) Serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with rheumatoid arthritis. *Mediators Inflamm* **7**:347-353.

Rose-John S, Waetzig GH, Scheller J, Grötzinger J, and Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. *Expert Opin Ther Targets* **11**:613-624.

Schmitt C, Kuhn B, Zhang X, Kivitz AJ, and Grange S (2011) Disease-drug-drug interaction involving Tocilizumab and Simvastatin in patients with rheumatoid arthritis. *Pharmacol Therapeutics* **89**:735-740.

Schrem H, Klempnauer J and Borlak J (2002) Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. *Pharmacol Rev.* **54**:129-158.

Schrem H, Klempnauer J and Borlak J (2004) Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. *Pharmacol Rev.* **56**:291-330.

Shedlofsky SI, Israel BC, McClain CJ, Hill DB, and Bouin RA (1994) Endotoxin administration to humans inhibits hepatic cytochrome P450 mediated drug metabolism. *J clin Invest* **94**:2209-2214.

Smith DE (2011) The biological paths of IL-1 family members IL-18 and IL-33 *J Leukoc Biol* **89**:1-10.

Sunman JA, Hawke RL, LeCluyse EL and Kashuba AD (2004) Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. *Drug Metab Dispos* **32**:359-263.

Vee ML, Lecureur V, Stieger B, and Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor- α or interleukin-6. *Drug Metab Dispos* **37**:685-693.

Yang J, Hao C, Yang D, Shi D, Song X, Luan X, Hu G, and Yan B (2010) Pregnane X receptor is required for interleukin-6 mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. *Toxicol Lett* **197**:219-226.

Legend for Figures

Fig. 1. The relative gene expression level of IL-6, IL-18 and their receptors IL-6r and IL18r, measured in untreated HepaRG cells (gray bar) and primary hepatocytes (black bar). The results are presented as the mRNA expression in each sample normalised by subtracting the endogenous control according to equation 1 in Material and Methods. HepaRG results are expressed as mean values from 3 plates with three pooled replicates per plate and the hepatocyte from one plate with two pooled replicates.

Fig. 2. The effect of proinflammatory cytokines on CRP gene expression in HepaRG cells (dark gray bar) and primary hepatocytes (black bar) after treatment with the highest concentration of IL-6 (30 and 50 ng/mL respectively) and IL-18 (500 ng/mL) for 48 hours. Data was normalized to untreated cells (light gray bar) and calculated as described under Materials and Methods, equation 1, 3 and 4. The HepaRG results are expressed as mean values from three plates with two or three pooled replicates per plate and the hepatocyte from one plate with duplicate (IL-6) or single (IL-18) incubations.

Fig. 3. The effect of IL-6 on CYP1A2 (A, B), CYP2B6 (C, D) and CYP3A4 (E, F) mRNA expression in human hepatoma cell line HepaRG (A, C, E) and primary hepatocytes (B, D, F). The results represent HepaRG cells treated for 48 hours with IL-6 (0.123 ng/mL-30 ng/mL) and primary hepatocytes treated with IL-6 (0.006-50 ng/mL). Results are expressed as mean values from three plates with three pooled replicates per plate (HepaRG) or one plate with duplicate incubations (hepatocytes).

Tables

Table 1. Suppression of gene expression for CYP1A2, CYP2B6 and CYP3A4 after treating HepaRG cells with increasing concentrations of LPS (1.37 -333 ng/mL), IL-6 (0.123-30 ng/mL) and IL-18 (2.06-500 ng/mL). Data were normalized to untreated cells and fitted to a four parameter dose-response model. Mean and standard deviation values are from three different plates. For IL-18, no E_{min} is quoted due to the lack of any dose-response.

Enzyme	LPS		IL6		IL18
	E_{min} (% of control)	EC_{50} ng/mL	E_{min} (% of control)	EC_{50} ng/mL	EC_{50} ng/mL
CYP1A2	28.8 ± 20.0	37.9	7.83 ± 5.30	0.452	>500
CYP2B6	31.3± 6.12	19.8	4.64 ± 0.98	0.388	>500
CYP3A4	4.39± 2.73	<1.37	0.998 ±0.418	<0.123	>500

Table 2. Suppression of gene expression for CYP1A2, CYP2B6 and CYP3A4 after treating primary hepatocytes with increasing concentrations of IL-6 (0.006-50 ng/mL) and IL-18 (1.95-500 ng/mL). Data were normalized to untreated cells and fitted to a four parameter dose-response model. Mean and standard deviation values are from two different wells. For IL-18, no E_{\min} is quoted due to the lack of any dose-response.

Enzyme	IL6		IL18
	E_{\min} (% of control)	EC_{50} ng/mL	EC_{50} ng/mL
CYP1A2	19.3 ± 9.46	5.49	>500
CYP2B6	22.4 ± 2.27	0.177	>500
CYP3A4	7.65 ± 3.43	0.454	>500

Table 3. Suppression of paracetamol (CYP1A2), hydroxybupropion (CYP2B6) and 1' hydroxymidazolam (CYP3A4) formation after treating HepaRG cells with increasing concentrations of LPS (1.37-333 ng/mL), IL-6 (0.123 -30 ng/mL) and IL-18 (2.06-500 ng/mL). Data were normalized to untreated cells and fit to a four parameter dose-response model. Mean and standard deviation values are from three different plates. For IL-18, no E_{min} is quoted due to the lack of any dose-response.

Enzyme	Metabolite	LPS		IL6		IL18
		E_{min} (% of control)	EC_{50} ng/mL	E_{min} (% of control)	EC_{50} ng/mL	EC_{50} ng/mL
CYP1A2	paracetamol	47.6 ± 7.2	>333	35.2 ± 7.7	8.96	>500
CYP2B6	hydroxybupropion	47.4 ± 2.18	116	20.4 ± 1.28	0.970	>500
CYP3A4	1'-hydroxymidazolam	39.1 ± 4.63	7.85	41.1 ± 3.44	2.89	>500

Figures





Figure 3

